The current status and challenges in multiple sclerosis management in the Philippines
Background The provision of adequate services for individuals living with multiple sclerosis
(MS) is an important issue since MS has a chronic and debilitating course. Objective We …
(MS) is an important issue since MS has a chronic and debilitating course. Objective We …
Ethical use of off-label disease-modifying therapies for multiple sclerosis
J Laurson-Doube, N Rijke, A Helme… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: Off-label disease-modifying therapies (DMTs) for multiple sclerosis (MS) are
used in at least 89 countries. There is a need for structured and transparent evidence-based …
used in at least 89 countries. There is a need for structured and transparent evidence-based …
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
K Allen-Philbey, S De Trane… - Therapeutic …, 2023 - journals.sagepub.com
Background: Cladribine is an effective immunotherapy for people with multiple sclerosis
(pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two …
(pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two …
Preventive neurology concepts for training the next-generation and closing gaps in real-world multiple sclerosis care
The field of Multiple sclerosis (MS) has entered an area of growth in the understanding of the
MS immune dysregulation that has led to an impressive therapeutics expansion. However …
MS immune dysregulation that has led to an impressive therapeutics expansion. However …
Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation
BI Yamout, S Viswanathan… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Therefore, in the current situation with this momentous result, implementation of the WHO
EML through the IGAP, or similar, frameworks will require coordinated leadership at national …
EML through the IGAP, or similar, frameworks will require coordinated leadership at national …
Multi-actor system dynamics in access to disease-modifying treatments for multiple sclerosis in Southeast Asia: A regional survey and suggestions for improvement
S Viswanathan, L Vijayasingham… - Multiple Sclerosis and …, 2024 - Elsevier
Background Despite the global availability of multiple sclerosis (MS) treatments, accessing
and financing them in Southeast Asia (SEA) remains a challenge. This descriptive survey …
and financing them in Southeast Asia (SEA) remains a challenge. This descriptive survey …
Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines
L Pandit - Multiple Sclerosis Journal, 2021 - journals.sagepub.com
Under these circumstances, in many LMICs, the burden of generating a standard of care for
MS has shifted substantially to the health care provider who shares this decision-making …
MS has shifted substantially to the health care provider who shares this decision-making …
[PDF][PDF] Ethical use of off-label disease-modifying therapies for multiple sclerosis
Background: Off-label disease-modifying therapies (DMTs) for multiple sclerosis (MS) are
used in at least 89 countries. There is a need for structured and transparent evidence-based …
used in at least 89 countries. There is a need for structured and transparent evidence-based …